FLT3-mutated Acute Myeloid Leukemia

Oncology·MeSH: Leukemia, Myeloid, Acute

Prevalence

30.0 / 100K

6 drugs in development·2 companies·1 clinical trial

Drug Pipeline by Phase

Compare drugs

daunorubicin or idarubicin vs fludarabinedaunorubicin or idarubicin vs mitoxantrone

Frequently asked questions

How many drugs are in development for FLT3-mutated Acute Myeloid Leukemia?

BioSniper tracks 6 drugs in development for FLT3-mutated Acute Myeloid Leukemia across 2 companies.

How many clinical trials target FLT3-mutated Acute Myeloid Leukemia?

There are 1 clinical trial targeting FLT3-mutated Acute Myeloid Leukemia tracked by BioSniper.

What is the prevalence of FLT3-mutated Acute Myeloid Leukemia?

The estimated prevalence of FLT3-mutated Acute Myeloid Leukemia is approximately 30.0 per 100,000 population.

Deep-dive into FLT3-mutated Acute Myeloid Leukemia

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis
    FLT3-mutated Acute Myeloid Leukemia — Drugs in Development & Clinical Trials | BioSniper